The global cell expansion market size is expected to reach USD 47.13 billion by 2030 registering a CAGR of 12.85%, according to a new report by Grand View Research, Inc. This strong growth trajectory is primarily driven by the rising implementation of automated systems in various cell expansion processes. The integration of automation significantly enhances operational efficiency in cell culture workflows, which in turn supports large-scale production.

Automated solutions play a crucial role in reducing manual intervention, thereby lowering labor requirements and overall production costs associated with Cell Therapy Products (CTP), gene therapies, and a wide range of biologics. These systems deliver more consistent, accurate, and reproducible results, ultimately leading to more robust manufacturing processes.

In response to the rapidly increasing global demand for CTP, major market participants are actively broadening their product portfolios. A notable example is Thermo Fisher Scientific, which in January 2021 launched the Gibco CTS OpTmizer Pro Serum Free Media platform. This advanced solution is designed specifically for the development and expansion of human T lymphocytes, particularly for cell therapy developers working with allogeneic workflows. By targeting donor cell metabolism, the platform supports the creation of allogeneic, off-the-shelf therapy products, helping streamline and accelerate development timelines.

Additionally, the industry is undergoing a major shift toward the adoption of Single-Use Systems (SUS), which provide significant manufacturing advantages. These systems eliminate the risk of cross-contamination and culture contamination that may occur due to improper sterilization of reusable equipment. Moreover, SUS allows manufacturers to achieve high-density cell growth while also offering long-term cost efficiency. As more companies integrate SUS into their manufacturing processes, the development and production of CTP are becoming increasingly scalable and reliable, ultimately contributing to robust market expansion.

Key Market Trends & Insights:

• North America accounted for the largest revenue share of 39.0% in 2022, highlighting the region’s strong presence in advanced biomedical research, well-established healthcare infrastructure, and early adoption of innovative cell-based technologies. This dominant position reflects the high concentration of key industry players, ongoing clinical research activities, and significant investments in cell-based therapies.

• Based on product, the consumables segment led the market in 2022, contributing 45.7% of the total market share. Consumables such as media, reagents, and growth factors are required continuously in cell expansion processes, which drives their consistent demand. Their essential role in ensuring optimal cell growth and maintaining culture quality supports their strong market position.

• Based on cell type, the mammalian cells segment held the highest revenue share in 2022. Mammalian cells are widely used in therapeutic development, vaccine production, and biopharmaceutical research due to their ability to produce complex proteins and closely mimic human biological systems, making them indispensable in modern biotechnology.

• Based on end-use, the biotechnology and biopharmaceutical companies segment accounted for the largest share of 46.3% in 2022. This is largely due to the increasing focus on developing advanced cell-based therapies, expanding R&D programs, and rising investments in manufacturing capabilities by industry leaders.

• Based on application, the biopharmaceutical segment captured the largest revenue share, underscoring the growing use of cell expansion technologies in the production of biologics, vaccines, and cell-based treatment solutions. The expanding pipeline of therapeutic products continues to strengthen this segment’s market dominance.

Order a free sample PDF of the Cell Expansion Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 17.75 Billion

• 2030 Projected Market Size: USD 47.13 Billion

• CAGR (2023-2030): 12.85%

• North America: Largest market in 2022

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key market participants are actively engaging in a variety of strategic initiatives aimed at strengthening their market presence and sustaining a competitive advantage. These companies are increasingly pursuing collaborations, partnerships, product development efforts, formal agreements, and business expansion activities, particularly in emerging or previously untapped regions. Such strategies help them broaden their technological capabilities, enhance product portfolios, and improve global reach.

For instance, in April 2022, STEMCELL Technologies Canada and Applied Cells Inc. formed a partnership to develop an advanced method for cell separation. This collaboration integrates the MARS platform developed by Applied Cells with STEMCELL’s EasySep kits, resulting in a more automated and simplified approach to isolating cells from various sample types. These samples may include whole blood, bone marrow, apheresis products, and tissue. The primary goal of this collaboration is to streamline and enhance cell isolation processes used in both research and medical applications, thereby improving overall efficiency, accuracy, and consistency.

In another significant development, in May 2023, panCELLa and BioCentriq entered into a research agreement to evaluate stem cell–derived Natural Killer (NK) cell expansion technology. This agreement focuses on assessing panCELLa’s genetically engineered feeder cells and their potential to improve the expansion rate, increase total NK cell yield, and enhance the functional potency of manufactured NK cells. The findings from this research are expected to support advancements in NK cell–based therapeutic development.

Key Players

• Thermo Fisher Scientific, Inc.

• Corning Incorporated

• Merck KGaA

• Miltenyi Biotec

• BD (Becton, Dickinson and Company)

• Terumo BCT, Inc.

• Sartorius AG

• Takara Bio Inc.

• TRINOVA BIOCHEM GmbH

• upcyte technologies GmbH

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global cell-expansion market is poised for robust growth, driven by increasing adoption of automated cell-culture and expansion solutions, growing demand for cell-based therapies, biologics, and regenerative-medicine products, and rising investment and activity by biotech and biopharma companies. Among market segments, consumables remain the dominant product category, while mammalian cells are the preferred cell type. Biopharmaceutical applications and biotechnology/biopharma firms lead end-use demand. Regionally, North America remains the largest market, with other regions beginning to gain traction.